comparemela.com

Latest Breaking News On - Foundation trust on part - Page 1 : comparemela.com

Guardant Health, Inc : Guardant Health and The Royal Marsden NHS Foundation Trust partner on highly anticipated TRACC Part C trial to use Guardant Reveal blood test to help guide treatment decisions in colorectal cancer

Trial will evaluate use of circulating tumor DNA to guide chemotherapy treatment decisions following surgery for stage II-III colorectal cancer patients based on test results for minimal residual

United kingdomHelmy eltoukhyAlex klebanDavid cunninghamGuardant healthNational institute of health researchExchange commissionGuardant health incGuardant health contactsGuardant health forwardInstitute of cancer researchRoyal marsden cancer charityResearch councilFoundation trust on partGuardant revealRoyal marsden

Guardant Health and The Royal Marsden NHS Foundation Trust partner on highly anticipated TRACC Part C trial to use Guardant Reveal blood test to help guide treatment decisions in colorectal cancer

19.01.2023 - Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, is partnering with The Royal Marsden NHS Foundation Trust on Part C of its “Tracking mutations in cell free DNA to predict Relapse in eArly Colorectal Cancer” (TRACC) study, . Seite 1

Guardant health incFoundation trust on partGuardant healthRoyal marsdenArly colorectalGuardant reveal

vimarsana © 2020. All Rights Reserved.